MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.
Anemia
MoReLife
Momelotinib
Myelofibrosis
Thrombocytopenia
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
20
05
2024
accepted:
19
07
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
Recurrent problems of patients with myelofibrosis (MF) are cytopenias, debiliating disease-related symptoms and splenomegaly. Whereas the latter are usually addressed by the JAK1/2 inhibitors ruxolitinib and fedratinib, cytopenias often remain critical. Momelotinib, a JAK1/2 inhibitor recently approved for the treatment of anemic MF patients, was shown to improve anemia via a direct inhibition of activin A receptor type I. In this German-wide, multicenter, retrospective analysis the safety and efficacy profile of momelotinib was evaluated in a real world setting within a cohort of 60 MF patients independent of pre-treatment. The median duration of treatment was 12 weeks. As a new, but manageable safety finding, creatinine increase (CTC°1-2) was detected in 10/60 patients (17%). Interestingly, not only hemoglobin levels increased in 84% of patients, but also platelet values (67%). In the cohort of transfusion-dependent individuals (n = 38), transfusion requirement improved in 15 patients (39%) with 8 reaching transfusion independency (21%). Transfusion independency was achieved within a median of 4 weeks (range 2-12). Spleen size decreased in 13/53 individuals (25%) with a median response time of 6 weeks. Thereof, 11 patients had been pre-treated with JAK inhibitor(s) (85%). Clinical improvement was detected in 24/51 symptomatic individuals (47%) with a median response time of 4 weeks. 5 patients stopped treatment due to side effects (8%), 6 patients due to a worsening of clinical symptoms (10%). Taken together, the MoReLife analysis identifies momelotinib as potent and safe therapeutic option also for heavily pre-treated cytopenic MF patients under real world conditions.
Identifiants
pubmed: 39073589
doi: 10.1007/s00277-024-05908-4
pii: 10.1007/s00277-024-05908-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Vainchenker W, Kralovics R (2017) Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 129(6):667–679. https://doi.org/10.1182/blood-2016-10-695940
doi: 10.1182/blood-2016-10-695940
pubmed: 28028029
Pizzi M, Croci GA, Ruggeri M, Tabano S, Dei Tos AP, Sabattini E, Gianelli U (2021) The classification of Myeloproliferative neoplasms: Rationale, historical background and future perspectives with focus on unclassifiable cases. Cancers (Basel) 13(22). https://doi.org/10.3390/cancers13225666
Birgegard G, Samuelsson J, Ahlstrand E, Ejerblad E, Enevold C, Ghanima W, Hasselbalch H, Nielsen CH, Knutsen H, Pedersen OB, Sorensen A, Andreasson B (2019) Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the nordic MPN study Group. Eur J Haematol 102(3):235–240. https://doi.org/10.1111/ejh.13198
doi: 10.1111/ejh.13198
pubmed: 30472746
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787–798. https://doi.org/10.1056/NEJMoa1110556
doi: 10.1056/NEJMoa1110556
pubmed: 22375970
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr., Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799–807. https://doi.org/10.1056/NEJMoa1110557
doi: 10.1056/NEJMoa1110557
pubmed: 22375971
pmcid: 4822164
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, Investigators C (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100(9):1139–1145. https://doi.org/10.3324/haematol.2014.119545
doi: 10.3324/haematol.2014.119545
pubmed: 26069290
pmcid: 4800694
Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115(25):5232–5240. https://doi.org/10.1182/blood-2009-05-223727
doi: 10.1182/blood-2009-05-223727
pubmed: 20385788
pmcid: 2892953
Gupta V, Mesa RA, Deininger MW, Rivera CE, Sirhan S, Brachmann CB, Collins H, Kawashima J, Xin Y, Verstovsek S (2017) A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 102(1):94–102. https://doi.org/10.3324/haematol.2016.148924
doi: 10.3324/haematol.2016.148924
pubmed: 27634203
pmcid: 5210237
Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A (2013) Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 27(6):1322–1327. https://doi.org/10.1038/leu.2013.71
doi: 10.1038/leu.2013.71
pubmed: 23459451
pmcid: 3677140
Asshoff M, Petzer V, Warr MR, Haschka D, Tymoszuk P, Demetz E, Seifert M, Posch W, Nairz M, Maciejewski P, Fowles P, Burns CJ, Smith G, Wagner KU, Weiss G, Whitney JA, Theurl I (2017) Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood 129(13):1823–1830. https://doi.org/10.1182/blood-2016-09-740092
doi: 10.1182/blood-2016-09-740092
pubmed: 28188131
pmcid: 5693322
Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, Platzbecker U, Giraldo P, Kosugi H, Sacha T, Mayer J, Illes A, Ellis C, Wang Z, Gonzalez Carreras FJ, Strouse B, Mesa R (2024) Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Leuk Lymphoma 1–13. https://doi.org/10.1080/10428194.2024.2328800
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R, Investigators MS (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet 401(10373):269–280. https://doi.org/10.1016/S0140-6736(22)02036-0
doi: 10.1016/S0140-6736(22)02036-0
pubmed: 36709073
Gerds AT, Verstovsek S, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Oh S, Klencke BJ, Yu J, Donahue R, Kawashima J, Mesa R (2023) Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol 10(9):e735–e746. https://doi.org/10.1016/S2352-3026(23)00174-6
doi: 10.1016/S2352-3026(23)00174-6
pubmed: 37517413
Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C (2023) Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv 7(14):3582–3591. https://doi.org/10.1182/bloodadvances.2022009311
doi: 10.1182/bloodadvances.2022009311
pubmed: 37042865
pmcid: 10368854
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J (2017) SIMPLIFY-1: a phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35(34):3844–3850. https://doi.org/10.1200/JCO.2017.73.4418
doi: 10.1200/JCO.2017.73.4418
pubmed: 28930494
pmcid: 6553796
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113(13):2895–2901. https://doi.org/10.1182/blood-2008-07-170449
doi: 10.1182/blood-2008-07-170449
pubmed: 18988864
Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A (2012) One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 87(1):25–33. https://doi.org/10.1016/j.mayocp.2011.11.001
doi: 10.1016/j.mayocp.2011.11.001
pubmed: 22212965
pmcid: 3538387
Scherber RM, Mesa RA (2020) Management of challenging myelofibrosis after JAK inhibitor failure and/or progression. Blood Rev 42:100716. https://doi.org/10.1016/j.blre.2020.100716
doi: 10.1016/j.blre.2020.100716
pubmed: 32593470
pmcid: 8895349
Bassiony S, Harrison CN, McLornan DP (2020) Evaluating the Safety, Efficacy, and therapeutic potential of Momelotinib in the treatment of Intermediate/High-Risk myelofibrosis: evidence to date. Ther Clin Risk Manag 16:889–901. https://doi.org/10.2147/TCRM.S258704
doi: 10.2147/TCRM.S258704
pubmed: 33061394
pmcid: 7524184
Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS (2018) Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol 97(3):435–441. https://doi.org/10.1007/s00277-017-3194-4
doi: 10.1007/s00277-017-3194-4
pubmed: 29189896
Naymagon L, Mascarenhas J (2017) Myelofibrosis-related Anemia: current and emerging therapeutic strategies. Hemasphere 1(1):e1. https://doi.org/10.1097/HS9.0000000000000001
doi: 10.1097/HS9.0000000000000001
pubmed: 31723730
pmcid: 6745971
Elena C, Passamonti F, Rumi E, Malcovati L, Arcaini L, Boveri E, Merli M, Pietra D, Pascutto C, Lazzarino M (2011) Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 96(1):167–170. https://doi.org/10.3324/haematol.2010.031831
doi: 10.3324/haematol.2010.031831
pubmed: 20884708
Chifotides HT, Bose P, Verstovsek S (2022) Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15(1):7. https://doi.org/10.1186/s13045-021-01157-4
doi: 10.1186/s13045-021-01157-4
pubmed: 35045875
pmcid: 8772195
Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM (2014) Use of the Functional Assessment of Cancer therapy–anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. Clin Ther 36(4):560–566. https://doi.org/10.1016/j.clinthera.2014.02.016
doi: 10.1016/j.clinthera.2014.02.016
pubmed: 24636526
Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96(1):145–162. https://doi.org/10.1002/ajh.26050
doi: 10.1002/ajh.26050
pubmed: 33197049
Rumi E, Trotti C, Vanni D, Casetti IC, Pietra D, Sant’Antonio E (2020) The genetic basis of primary myelofibrosis and its clinical relevance. Int J Mol Sci 21(23). https://doi.org/10.3390/ijms21238885
How J, Hobbs GS (2020) A practical guide for using myelofibrosis prognostic models in the clinic. J Natl Compr Canc Netw 18(9):1271–1278. https://doi.org/10.6004/jnccn.2020.7557
doi: 10.6004/jnccn.2020.7557
pubmed: 32886896
Nicolosi M, Mudireddy M, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A, Tefferi A (2018) Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. Leukemia 32(5):1254–1258. https://doi.org/10.1038/s41375-018-0028-x
doi: 10.1038/s41375-018-0028-x
pubmed: 29568091
pmcid: 5940639
Griffiths EA (2024) Transfusion avoidance in myelodysplastic neoplasms. Curr Opin Hematol 31(2):40–46. https://doi.org/10.1097/MOH.0000000000000794
doi: 10.1097/MOH.0000000000000794
pubmed: 37982261
Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, Scott BL, Kiladjian JJ, Lucchesi A, Kong T, Buckley SA, Tyavanagimatt S, Harder BG, Roman-Torres K, Smith J, Craig AR, Mascarenhas J, Verstovsek S (2023) Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 7(19):5835–5842. https://doi.org/10.1182/bloodadvances.2023010151
doi: 10.1182/bloodadvances.2023010151
pubmed: 37552106
pmcid: 10561048
Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol 5(2):e73–e81. https://doi.org/10.1016/S2352-3026(17)30237-5
doi: 10.1016/S2352-3026(17)30237-5
pubmed: 29275119
Tefferi A, Pardanani A, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Ketterling RP, Reichard KK, Gangat N (2024) Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant. Blood Cancer J 14(1):51. https://doi.org/10.1038/s41408-024-01028-4
doi: 10.1038/s41408-024-01028-4
pubmed: 38503764
pmcid: 10951334